Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:20 PM
Ignite Modification Date:
2025-12-24 @ 2:20 PM
NCT ID:
NCT01705795
Eligibility Criteria:
Inclusion Criteria:
* Men, women \>18 years
* Active BP (diagnosed by typical clinical picture and skin biopsy)
* Must give written informed consent
Exclusion Criteria
* Patients with other skin disease
* Patients with severe diseases of other organ systems
* Systemic treatment for BP
* Topical therapy with corticosteroids and other anti-inflammatory substances
* For female patients, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception (defined as methods with \<1% failure rate)
* Female patients who are currently pregnant or breast-feeding
* Current abuse of alcohol and/or drugs
* History of or a new diagnosis or treatment of an invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded.
* History of recurrent clinically significant infection
* Congenital or acquired immunodeficiency syndrome
* Current enrollment in any other investigational drug study
* Previous participation in this study or previous studies with mepolizumab
* Hypersensitivity to mepolizumab or its constituents
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01705795
Study Brief:
Protocol Section:
NCT01705795